Apolipoprotein L1 Genetic Variants Are Associated with Chronic Kidney Disease but Not with Cardiovascular Disease in a Population Referred for Cardiac Catheterization

Abstract

Background: While the association between APOL1 genetic variants and chronic kidney disease (CKD) has been established, their association with cardiovascular disease (CVD) is unclear. This study sought to understand CKD and cardiovascular risk conferred by APOL1 variants in a secondary cardiovascular prevention population. Methods: Two risk variants in APOL1 were genotyped in African-Americans (n = 1,641) enrolled in the CATHGEN biorepository, comprised of patients referred for cardiac catheterization at Duke University Hospital, Durham, NC, USA (2001-2010). Individuals were categorized as noncarriers (n = 722), heterozygote (n = 771), or homozygote carriers (n = 231) of APOL1 risk alleles. Multivariable logistic regression and Cox proportional hazards models adjusted for CVD risk factors were used to assess the association between APOL1 risk variants and prevalent and incident CKD, prevalent coronary artery disease (CAD), incident CVD events, and mortality. Results: The previously identified association between APOL1 variants and prevalent CKD was confirmed (OR: 1.85, 95% CI: 1.33-2.57, p = 0.0002). No statistically significant associations were detected between APOL1 variants and incident CKD or prevalent CAD, incident CVD events or mortality. Age, type 2 diabetes, and ejection fraction at baseline were significant clinical factors that predicted the risk of incident CKD in a subgroup analysis of APOL1 homozygous individuals. Conclusion:APOL1 genetic variants are not associated with CAD or incident CVD events in a cohort of individuals with a high burden of cardiometabolic risk factors. In individuals with homozygous APOL1 status, factors that predicted subsequent CKD included age, presence of type 2 diabetes, and ejection fraction at baseline.

Statins and New-Onset Diabetes in Cardiovascular and Kidney Disease Cohorts: A Meta-Analysis

“…The benefits of preventing major adverse cardiovascular outcomes in patients with and without diabetes in comparison to the small, yet significant, risk of NODM is favorably balanced by the cardiovascular benefits [35-38]. This suggests that clinical decision-making should not change, especially for those with a medium or high risk of cardiovascular events or existing cardiovascular disease.…”

Association of APOL1 With Heart Failure With Preserved Ejection Fraction in Postmenopausal African American Women

“…12 Associations of APOL1 alleles with cardiovascular disease and mortality were reported in African American participants of the Jackson Heart Study and among Medicareeligible participants of the Cardiovascular Health Study but not in subsequent cross-sectional and longitudinal studies. 5,[13][14][15][16][17] Differences in study design, outcome type, and the number of events in these studies may account for inconsistencies.…”

APOL1Nephropathy Risk Variants and Incident Cardiovascular Disease Events in Community-Dwelling Black Adults

“…14,19,38 In contrast, in studies enrolling participants with known risk factors for CVD, including referral for cardiac catheterization, hyper-tension, and CKD, the association between APOL1 high-risk status and incident CVD was weak or absent, perhaps because it was masked by the stronger risk conferred by underlying morbidities. 12,13,39 Relative proportions of European and African ancestry are also potential confounders. Europeans are at greater risk for atherosclerosis, and similarly, increasing European ancestry in Black Americans is associated with more coronary calcification and atherosclerosis, which are predictors of CVD.…”